Document Detail


Compensation of muscarinic bronchial effects of talsaclidine by concomitant sympathetic activation in guinea pigs.
MedLine Citation:
PMID:  9253956     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim of the present investigation was to determine the reasons why the muscarinic receptor agonist talsaclidine (WAL 2014 FU, 1-azabicyclo[2.2.2] octane,3-(2-propynyloxy)-, (R)-,(E)-2-butenedioate) is devoid of bronchospastic effects in anaesthetized guinea pigs but causes contracture in isolated tracheal muscle from this species. Effects on airway resistance were assessed with a modified Konzett-Rossler method in guinea pigs anaesthetized with urethane. Intravenous injection of 1-64 mg/kg talsaclidine did not cause substantial bronchospasm in control animals. After blockade of beta-adrenoceptors, the muscarinic receptor agonist induced dose-dependent bronchospasm which could be blocked by atropine. In despinalized animals and in animals with spinal transection, talsaclidine was bronchospastic but ED50 values were higher and maximal effects were smaller than in intact animals after beta-adrenoceptor blockade. In adrenalectomized guinea pigs, talsaclidine was nearly as bronchospastic as after blockade of beta-adrenoceptors. In contrast, the muscarinic ganglion stimulant McN-A-343, 4-(m-chlorophenylcarbamoyloxy)-2-butyn-trimethyl-ammonium chloride, (2-32 mg/kg i.v.), which has a muscarinic receptor profile similar to that of talsaclidine, i.e., full muscarinic agonism and highest affinity at muscarinic M1 receptors, partial agonism at muscarinic M3 receptors, but in contrast to talsaclidine does not penetrate the blood-brain barrier, caused dose-dependent bronchospasm in control animals. These results indicate that talsaclidine has bronchospastic potential which, however, does not become evident in vivo because of functional antagonism via beta-adrenoceptors resulting from concomitant activation of the sympathetic nervous system in general and the adrenals in particular. It can be concluded that the unique profile of action of talsaclidine is due to partial agonism at bronchial muscarinic M3 receptors, a prerequisite for susceptibility to functional antagonism, and to its ability to penetrate the blood-brain barrier readily and to induce sympathetic activation as a result of full agonism at peripheral ganglionic and adrenal as well as central muscarinic M1 receptors.
Authors:
A Walland; R Palluk; S Burkard; R Hammer
Related Documents :
19730136 - Muscarinic m1 modulation of acid-sensing ion channels.
11311896 - Regulation of phospholipase cbeta activity by muscarinic acetylcholine and 5-ht(2) rece...
3973676 - Quantitative in vivo receptor binding. i. theory and application to the muscarinic chol...
17473176 - Neuronally released acetylcholine acts on the m2 muscarinic receptor to oppose the rela...
23567896 - Pentamerisation of a scfv directed against trail receptor 2 increases its antitumour ef...
3443966 - Behaviour of canine pulmonary vagal afferent receptors during sustained acute pulmonary...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of pharmacology     Volume:  330     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  1997 Jul 
Date Detail:
Created Date:  1997-09-22     Completed Date:  1997-09-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  213-9     Citation Subset:  IM    
Affiliation:
Department of Biological Research, General Pharmacology, Boehringer Ingelheim KG, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride / pharmacology
Adrenergic beta-Antagonists / pharmacology
Animals
Arecoline / pharmacology
Bronchi / drug effects*,  innervation*,  ultrastructure
Bronchial Spasm / chemically induced*
Dose-Response Relationship, Drug
Drug Interactions
Guinea Pigs
Male
Muscarinic Agonists / pharmacology*
Nicotinic Antagonists / pharmacology
Quinuclidines / pharmacology*
Rats
Receptors, Muscarinic / drug effects
Receptors, Nicotinic / drug effects,  physiology
Spinal Cord / physiology,  surgery
Sympathetic Nervous System / drug effects,  physiology*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Muscarinic Agonists; 0/Nicotinic Antagonists; 0/Quinuclidines; 0/Receptors, Muscarinic; 0/Receptors, Nicotinic; 147025-54-5/talsaclidine fumarate; 55-45-8/(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; 63-75-2/Arecoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Renal vasoconstrictor response to 5-hydroxytryptamine in the in situ autoperfused rat kidney: involv...
Next Document:  Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide.